Draupnir Bio ApS. (10/19). "Press Release: Draupnir Bio Secures Euro 30 Million in Series A Funding Round".

	Organisation	Draupnir Bio ApS
	Organisation 2	High-Tech Gründerfonds Management GmbH
	Group	High-Tech Gründerfonds (HTGF) (Group)
	Product	PCSK9 inhibitor
	Product 2	venture capital
	Index term	Draupnir Bio–SEVERAL: investment, 201910 financing round Series A DKK225m (€30m) from Novo Seeds + Gilde Healthcare + HTGF
	Index term 2	Draupnir Bio–High-Tech Gründerfonds: investment, 201910 financing round Series A totalling DKK225m (€30m) incl existing investor HTGF
	Person	Glerup, Simon (Draupnir Bio 202106– CSO before CEO + Co-Founder)
	Person 2	Seeberger, Peter H. (MPI of Colloids and Interfaces 2009– Director before ETH Zurich Prof before MIT Prof)

In October 2019, Draupnir Bio (“Draupnir”), the biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, announced the completion of a Series A funding round, raising DKK 225M (Euro 30M) in capital investment.

The funding – one of the largest early investments in a Danish biotechnology company – was supported by a syndicate of leading European healthcare and life-sciences investors. Novo Seeds, Gilde Healthcare, Inkef Capital and High-Tech Gründerfonds all participated in the round.

Draupnir Bio was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. Its research is based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels.

At the time of its founding by Simon Glerup, Camilla Gustafsen, Peder Madsen and Peter Seeberger, Draupnir received a DDK 2.5M (€336,000) grant from the Novo Nordisk Foundation and access to DDK 15M (€2M) seed funding from Novo Seeds and High-Tech Gründerfonds.

-ENDS-

For more information, please contact:

Draupnir Bio
Simon Glerup, Chief Executive Officer
Email: [email protected]

Consilium Strategic Communications
David Daley, Genevieve Wilson, Alexander Bridge
Phone: +44 (0)20 3709 5700
Email: [email protected]

Notes to editors

About Draupnir Bio

Draupnir Bio is a Danish biotechnology company developing small molecule therapeutics to transform the treatment of heart disease, based on proprietary structural insights and the biology of Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9), a protein that enables a key step in the control of plasma low density lipoprotein cholesterol (LDLC) levels. The company was founded in 2017 as a spin-out from Aarhus University, Denmark, and the Max-Planck Society, Germany. Backed by a syndicate of leading European investors, in 2019 Draupnir Bio completed a Series A funding round, raising €30 million Euros with participation from Gilde Healthcare Partners, Inkef Capital, Novo Seeds and High-Tech Gründerfonds. The company is headquartered in Copenhagen, with research operations centered in Aarhus, Denmark.

Record changed: 2024-12-22